"ARVs is for HIV and cream is for HPV or precancer:" Women's Perceptions and Perceived Acceptability of Self-Administered Topical Therapies for Cervical Precancer Treatment: A Qualitative Study from Kenya

- 2 Chemtai Mungo,^{1,2} Aparna Ghosh Kachoria,³ Everlyn Adoyo,⁴ Graham Zulu,⁵ Supreet Kaur Goraya,
- ³ Jackton Omoto,⁶ Cirilus Osongo,⁴ Renée M. Ferrari,^{2,3} Lisa Rahangdale^{1,2}
- 4

1

5 Affiliations:

- 6 1. Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at
- 7 Chapel Hill, Chapel Hill, NC 27599, USA
- 8 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel
- 9 Hill, NC 27599, USA
- 10 3. Department of Maternal and Child Health, Gillings School of Global Public Health, University of
- 11 North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
- 12 4. Kenya Medical Research Institute, Kisumu, Kenya
- 13 5. Butler Institute for Families, University of Denver, Denver, CO 80210, USA
- 14 6. Department of Obstetrics and Gynecology, Maseno University School of Medicine, Kisumu,
- 15 Kenya
- 16
- 17 *** Correspondence:**
- 18 Chemtai Mungo, MD, MPH
- 19 Chemtai_mungo@med.unc.ed

20

21

23 Abstract [349/350 words]

24 Background: Women in low- and middle-income countries (LMICs) bear a disproportionate burden 25 of global incidence and deaths from cervical cancer, despite being a preventable disease. Prevention 26 efforts in LMICs are hindered in part by lack of access to cervical precancer treatment, due to weak 27 health infrastructure and a lack of adequate human resources to deliver current provider-administered 28 precancer treatments. Innovative strategies are urgently needed to close the cervical precancer 29 treatment gap in LMICs, including the use of self-administered topical therapies for which efficacy 30 evidence is available from high-income settings. We investigated African women's perceptions and 31 perceived acceptability of these therapies for cervical precancer treatment. 32 Methods: Between November 2022 and April 2023, we conducted five focus group discussions 33 (FGDs) with women ages 25-65 years undergoing cervical cancer screening or precancer treatment in 34 Kisumu, Kenya. The FGDs explored women's experiences with screening and precancer treatment, 35 their acceptability of topical therapies for precancer treatment, and perceived barriers and facilitators 36 to uptake. The FGDs were moderated by local qualitative research assistants, conducted in local 37 languages, transcribed, coded, and analyzed using qualitative description using NVIVO software. 38 **Results:** Twenty-nine women participated, with a mean age of 35.4 years (SD 6.5). All had 39 undergone cervical cancer screening, and 25 (83%) had a history of precancer treatment with ablation 40 or excision. Multiple themes were identified related to women's perceptions of topical therapies. 41 Participants were highly receptive of topical treatments, with many favoring the option of self-42 administration compared to provider-administration of such therapies. Self-administration of topical 43 therapies was felt to help address challenges associated with current treatment methods, including 44 difficulty in access, pain with procedures, cost, and lack of privacy with pelvic exams. Participants 45 had a preference for topical therapies that are used less frequently compared to those used daily.

46	Conclusions: Among Kenyan women with a history of cervical precancer treatment, self-
47	administered topical therapies for precancer are acceptable and have the potential to address barriers,
48	including access, privacy, and cost, that hinder precancer treatment in LMICs. If supported by
49	efficacy studies in LMICs, self-administered topical therapies offer a scalable approach to closing the
50	precancer treatment gap in LMICs.
51	Trial registration: Not applicable
52	Keywords: cervical precancer treatment, topical therapies, self-administered treatment,
53	cervical cancer elimination, low- and middle-income countries, women living with HIV,
54	cervical cancer, sub-Saharan Africa
55	
56	
57	
58	
59	
60	
61 62	
62 63	
64	
65	
66 67	
0/	

68 Background

69	Women in low- and middle-income countries (LMICs) shoulder a disproportionate burden of the
70	incidence and mortality from cervical cancer, accounting for 85 percent of cases and 90 percent of
71	deaths in 2020[1]. Additionally, women living with HIV (WLWH), the majority of whom live in
72	LMICs, are six times more likely to develop cervical cancer and, hence, are a priority population for
73	prevention[2], [3]. In response to this, the World Health Organization (WHO) launched the 90/70/90
74	global strategy to eliminate cervical cancer[4]. This strategy, adopted by most WHO member states,
75	calls for 90% human papillomavirus (HPV) vaccination coverage of all girls by the age 15 years,
76	70% of women globally receiving cervical cancer screening with a high-performance test at least
77	twice in their lifetime, and 90% of those with a positive result adequately treated by 2030[4].
78	Modeling studies demonstrate that achieving the 90/70/90 targets will avert 74 million new cases of
79	cervical cancer and 62 million deaths in LMICs alone[5].
80	
81	Among unvaccinated women, cervical cancer can be prevented through screening for and treating
82	early changes in the cervix, known as cervical precancer, caused by HPV infection. Current cervical
83	precancer treatment options include ablation or excision procedures, both of which are performed by
84	trained healthcare professionals[6]. Despite progress in screening, access to cervical precancer
85	treatment following abnormal screening results in LMICs is highly limited[7], [8], [9], [10][11]. In a
86	review of the Kenya national cervical cancer screening program in 2021, only 26% of 10,983 women
87	who screened positive for cervical precancer received treatment [12]. Similarly, between 2011 and
88	2015 in Malawi, only 43.3% and 31.8% of women with cervical precancer who required ablation or
89	excision, respectively, received treatment[13]. Challenges associated with precancer treatment in
00	

91	screened in rural areas are referred to central facilities where treatment is available, due to a lack of
92	skilled healthcare providers in rural areas where most women live [9], [10], [11], [12], [14], [15]. The
93	failure to treat precancerous lesions while at a curable stage in these settings results in 85% of new
94	global cervical cancer cases occurring in LMICs, highlighting a significant disparity. This highlights
95	the urgent need for innovative yet resource-appropriate approaches to address the gap in cervical
96	precancer treatment in LMICs. One potential strategy is the use of self-administered topical therapies.
97	
98	While no topical therapies are currently approved for the treatment of cervical precancer, the use of
99	self- or provider-administered topical therapies for cervical precancer treatment is an area of active
100	investigation [16], [17], [18], [19], [20], [21], [22], [23]. The feasibility, acceptability, and efficacy of
101	topical therapies for cervical precancer treatment has been demonstrated by several studies in high-
102	income countries, including randomized trials[16], [17], [20], [24]. Several of these drugs are on the
103	WHO List of Essential Medications and are readily available in LMICs in generic form[25]. One
104	such drug is Fluorouracil (5FU) cream, which has been demonstrated to be a safe and effective
105	cervical precancer treatment when self-administered intravaginally[16], [17]. Compared to provider-
106	administered precancer treatment, which is currently inaccessible for many women in LMICs,
107	patient-administered therapies may be a highly scalable and cost-effective cervical precancer
108	treatment method in these settings.
109	
110	To inform ongoing (Clinicaltrials.gov identifier NCT05362955, NCT06165614, NCT05413811) and
111	future studies on topical therapies for cervical precancer in LMICs, studies on their acceptability and
112	barriers to uptake among both women and their male partners in LMICs are needed. The objective of

this study was to assess how African women receiving cervical cancer screening and precancer

- 114 treatment perceive the use of topical therapies for cervical precancer treatment and their potential 115 acceptability of such therapies were they to be available.
- 116 Methods

117 **Study design and approach:** This study is part of a larger project exploring the acceptability of 118 topical therapies for the treatment of HPV and cervical precancer, which included in-depth interviews 119 and focus groups with women undergoing cervical cancer screening and male partners in Kenya, in 120 eastern Africa. Results of a qualitative analysis of men's perspectives have been reported elsewhere 121 [23]. This current analysis encompasses focus group discussions with female participants. [26] We 122 used a constructivist paradigm to gather perspectives of women introduced to the idea of a novel 123 treatment method for HPV or cervical precancer. Constructivism suggests that knowledge is 124 constructed through individual perceptions, experiences, and social contexts [27]. We hypothesized 125 that acceptability of topical therapies is based on women's experiences (e.g., prior treatment 126 experiences, knowledge of other women's experiences) and their social contexts (e.g., relationships 127 with sexual partners).

128

129 We used focus group discussions (FGDs) to gather the breadth and depth of experiences from groups 130 of women. A predetermined sample size of five focus groups was selected based on evidence 131 indicating that most themes can be captured within a range of three to six focus groups [28]. Since 132 the topical treatment being proposed is innovative within this study's context, we conducted an 133 analysis of the data using qualitative description, which is highly suitable for enhancing 134 comprehension in a field with limited knowledge [29]. As this method remains focused on the data 135 itself and involves minimal interpretation, qualitative description effectively facilitated our objective 136 of providing a clear and direct account of the participants' perceptions, thoughts, and experiences.

1	2	7
1	J	1

138	Research Team: The principal investigator (CM), a Kenyan-born Obstetrician/Gynecologist with 10
139	years of experience, graduate students in medicine, social work, and public health (AGK, GZ, SKG),
140	and a senior qualitative investigator with 20 years of experience in qualitative methods and health
141	services research (RMF) comprised the research team. The focus groups were facilitated and
142	transcribed by two qualitative research assistants from the local community.
143	
144	Sampling, recruitment, and data collection: We used purposive sampling and a stepped
145	recruitment process to recruit FGD participants, as described previously[23] [30]. Women age 25 to
146	65 years undergoing cervical cancer screening or precancer treatment in public clinics in western
147	Kenya between November 2022 and April 2023 were included in the study. Emphasis was placed on
148	recruiting women with a history of positive screening results or prior precancer treatment.
149	Participants were recruited from HIV clinics as well as clinics serving the general population. Most
150	women had undergone cervical cancer screening using HPV self-collection, which was available at
151	most clinics at the time of recruitment. Per the WHO guidelines, women who screened positive were
152	offered treatment with thermal ablation or referred for excision if not eligible for ablation (6). Using
153	focus group discussions (FGDs), we explored the women's perceptions and hypothetical
154	acceptability of using proposed topical, self-administered therapies for treatment of HPV or cervical
155	precancer, should such therapies become available for public use.
156	
157	The FGDs were conducted by two female moderators from the same community as the research
158	participants (EA, JO). The moderators had training in qualitative research, prior experience
159	conducting focus group discussions, familiarity with the local context, and fluency in the local
160	languages. FGDs were held at facilities near the recruiting clinics and conducted in the two most

161 spoken local languages (Swahili and Dholuo). Discussions were guided by several domains of 162 inquiry: 1) baseline knowledge of HPV and cervical cancer screening and prevention, 2) the primary 163 treatment experience and perceived efficacy of treatment, 3) acceptability of self-administered topical 164 therapies as primary or adjuvant treatment to current therapies, 4) self-perceived barriers to use of topical therapies, and 5) perceived barriers or facilitators of male partner's support for the use of 165 166 topical therapies as adjuvant treatment. Moderators used standardized language to explain cervical 167 cancer screening and prevention and the potential option of topical self- or provider-administered 168 therapies for precancer treatment. Briefly, participants were introduced to two topical therapies for 169 which data are available, 5-FU and Artesunate, including details on their frequency of use (5-FU 170 once every other week for eight applications, Artesunate daily for five days for three cycles), 171 abstinence requirements (two to three days of abstinence after each 5-FU application and none for 172 Artesunate). Participants were told that tampon use overnight was recommended following 173 application of the topical, and tampons were available for illustration using a pelvic model for those 174 who had never used one. Each FGD included 5-8 participants and lasted approximately 90 minutes. 175 All FGDs were audio recorded, and recordings were transcribed verbatim, translated to English, and 176 crosschecked to confirm accuracy.[31]

177

178 Data Analysis: A codebook was created a priori based on the focus group guide. Two coders (GZ,

SKG) read and coded two of the five FGDs to test the code application and gain a sense of additional
topics covered in the group discussions, adding emergent codes (e.g., informational needs,

181 interactions with health service providers) to a final codebook. All FGD transcripts were coded using

182 the final codebook. To ensure agreement between coders, a random sample of transcripts was chosen,

and the codes were compared for concurrence. Any inconsistencies were addressed through

184 discussion and mutual agreement, and any modifications made were recorded in the codebook. The

- team reviewed and summarized code reports and explored the data for patterns and themes. Content
- analysis and thematic development were supported using NVIVO Version 13. Although the focus
- 187 group discussions covered multiple topics, this analysis focuses on three primary topics: 1)
- 188 participants' knowledge and awareness of cervical cancer; 2) treatment preferences and comfort with
- topical therapy; and 3) perceived acceptability of topical therapy for cervical precancer treatment
- 190 (Figure 1).
- 191 Figure 1. Summary of themes regarding women's perceptions of topical, self-administered therapies
- 192 for cervical precancer treatment



- Participants generally favored night time application of a topical cream, especially during menstruation
 There was mild concern about the tedious nature of self application for some treatments in terms of tampon use, anatomy, and self-confidence in applying the treatment correctly
- Perceived Topical Therapy Acceptability
 - Participants appreciated the potential ease of topical therapy application discretely in their homes (or in clinics)
 - •There was higher acceptability for the treatment among women with higher awareness of cervical cancer
- 193
- 194 **Results**
- 195 A total of 29 women participated in five FGDs. The mean age was 35.4 years (SD 6.5). The majority,
- 196 25 (83.3%), had a history of prior precancer treatment, including during the visit they were recruited
- 197 into the study. Analysis of the FGDs identified 15 themes related to the potential use of self-

- administered topical therapies for cervical precancer treatment in the study population, summarized
- in Figure 2.

201

202

200 Figure 2. Key findings on women's general perceptions of topical therapies



203 Participant Experiences with Cervical Cancer Screening and Precancer Treatment

204	FGD participants shared their experiences of learning their HPV or cervical precancer diagnosis
205	following screening. Many mentioned having symptoms of pelvic pain or bleeding during intercourse
206	and wanting to see a doctor for screening and treatment to learn more.
207	"I was suspecting something was wrong because I had some pelvic pain and also some spots
208	whenever I had sex, I would have some blood spotting. And I used to hear that those are some
209	of the symptoms suggestive of cervical cancer." -R4, FGD1
210	
211	Others underwent cervical cancer screening after being advised to do so by clinic staff. One woman
212	shared on why she had screening.
213	"I cannot refuse because each person just wants good health. They tested and told me that I
214	would be called by somebody after some time." -R6, FGD4
215	
216	While there was acknowledgment and awareness of the symptoms of cervical cancer, awareness of
217	HPV was less common. Following notification of a positive HPV test, some participants noted that
218	they were initially not aware of the difference between HPV and cervical precancer or cancer, and
219	they often needed to seek more information to understand the differences.
220	"When I was told that I was HPV positive from the screening test results, I was very afraid
221	from that day and all I could do was to GOOGLE about it and learn as much as I could. But
222	what calmed me down was that when I was being treated for the HPV, I was told that having
223	HPV doesn't mean that I have cancer. It can be treated early before it progresses to cancer."
224	- R7, FGD3
225	

226	Generally, participants shared that knowledge and awareness led to greater acceptance of the
227	recommended treatment, particularly as it relates to the difference between receiving an HPV or
228	cervical cancer diagnosis.
229	"I discovered after reading a lot of different materials and I also consulted from other people
230	that I found that virus [HPV] is different from cancer."- R7, FGD1
231	
232	"I was told that having HPV doesn't mean I have cancer and so when I went through
233	treatment, I didn't feel much pain except for the day of treatment, but for a few minutes then I
234	was told to abstain for 6 weeks for the cervix to heal. Then I followed that, and I feel better
235	<i>now</i> ." - R7, FGD3
236	
237	Some women recounted their clinic experiences, noting how they felt when they had nice providers
238	compared to others who had previously scared them in some way, an important factor in accepting
239	the news of their screening and the precancer treatment they were prescribed:
240	"My test results for my last precancer test are out, and they are positive, and I needed to
241	come for more information and treatment[the staff] lady who called talked to medidn't
242	scare me she talked nicely to me then I came [to the hospital]. I was treated and I was told
243	the discharge will be there for one week, 10 days. But what I felt when I was being treated, I
244	was counseled first, I felt some cramps for some minutes, and I even screamed a little there."
245	-R2, FGD3
246	
247	The focus groups highlighted how participants' experiences varied in learning about their screening

248 results and becoming aware of the treatment options available. The discussions consistently showed

249	that participants' understanding of HPV and cervical cancer-from prevention through screening to
250	treatment—played a crucial role in overcoming stigma and pursuing treatment after their diagnosis.
251	
252	Experiences with Ablative or Excisional Precancer Treatment and Perceived Advantages of
253	Topical Therapies
254	During the FGDs, participants shared their experiences with traditional precancer treatments (thermal
255	ablation, cryotherapy, excision) and were introduced to intravaginal topical therapies (creams or
256	suppositories) currently being studied that can be self- or provider-administered. Participant's views
257	on these topical therapies, their potential integration into their lives, and comparisons with traditional
258	treatments were explored.
259	
260	Many FGD participants showed a greater preference for topical treatments over traditional precancer
261	treatments, which many had undergone, citing topical therapies perceived fewer side effects,
262	especially pain, compared to treatments they had received.
263	"What I feared was the LEEP [Loop electrosurgical excision procedure, a surgical precancer
264	treatment method] and secondly the chemoablation [thermal ablation]. A friend who came
265	from treatment would tell us that it is painful, and even the doctor told us that there will be
266	pain during the procedure, especially during heat application. And for sure, [thermal
267	ablation] was painful just as labor pains." R1, FGD5
268	
269	"[Given a choice] I would choose cream because the cream I will use in the house unlike
270	thermo [thermal ablation] that I will have to come to the hospital, [which takes time]
271	thermo is too painful." R5, FGD1

273	"During [thermal ablation] treatment procedure, there is short pain that you feel. And so I
274	can encourage people that it is not a very painful experience because when some people hear
275	about it, then they develop fear to the extent that they don't even go for treatment. I have a
276	friend who dropped [out of treatment], she feared thinking that it is a painful experience.
277	Therefore, I can encourage everybody to go for treatment and that there is no serious pain
278	except a short time during the procedure, which is normal like when being injected, you feel
279	pain and after that the pain disappears. So, we should all go for treatment, there is no
280	problem with it." – $R2$, FGD4
281	
282	"[With ablation,] during treatment, they were removing certain things [like] cotton wool and
283	in addition to that my sister had also said to me that there is a chemical they will spray, which
284	they did and I felt abdominal pain. I felt pain during treatment, but I just persevered for the
285	sake of treatment so that I get well." - R4, FGD4
286	
287	Many were happy to hear of the potential for a self-treatment option that could be done in their own
288	home, which they felt could better fit into their daily lives, offered more privacy and less discomfort
289	compared to provider-administered treatments:
290	"I can prefer cream because that other thermos [thermal ablation] treatment or cryo
291	[cryotherapy], they use strange objects in the cervix and that brings tension and discomfort
292	because the objects going into the cervix makes you tensed and then again that type of
293	treatment [cryotherapy] doesn't involve one person, you find that three or two people want to
294	deal with your cervix and this brings some discomfort. But this one you are alone with your
295	husband whom you are used to, there is no fear." R7, FGD1

0	O	6
	フ	υ.

297	"I can choose [the] cream because it has some level of confidentiality, you know women don't
298	like it when someone is looking at her private part. So, some people can fail to go back to the
299	hospital because they don't want the doctor to look at their private part and with [the] cream
300	you apply it yourself and you are the only one who know how your private part looks like
301	[laughter] so I can choose this one" – R4, FGD1
302	
303	"[I prefer the] cream because I apply it at my own free time, secondly, I don't have to go see
304	clinician all the time, it gives you privacy. You see the society where we live, people will
305	quicky judge you wrongly if you are seen [in front] of the clinician all the time." – R1, FGD4
306	
307	"The [treatment at] the hospital that you go to be checked by the doctor, you must at least be
308	seen by a person when on your way there and there is no privacy there. This cream is private,"
309	-R4, FGD1
310	
311	Others cited the convenience and accessibility of a topical therapy that can be self-administered at
312	home as an advantage, compared to the time and costs associated with visiting clinics for provider-
313	administered treatments.
314	"[the] cream is good due to lack of transportation all the time when going for other treatment
315	methods. Again, I don't have to make a queue in the hospital waiting to be treated because
316	once I get the cream, I will be applying it by myself at home." – R3, FGD4
317	

318	"I will choose cream due to cost if transportation to the hospital all the time to go for other
319	treatment methods, but with cream I take it once and continue to apply by myself at home." –
320	R2, FGD4
321	
322	Some also noted a sense of increased autonomy or empowerment with use of self-administered
323	topical therapies, which some felt would support compliance.
324	"If I can be given this cream to take home, nothing can bar me from using [the] cream, I am
325	just being empowered and I use it accordingly." – R7, FGD2
326	"I think that cream is very good. You cannot fear your own body and therefore you will insert
327	it very well because you want to get cured fully." – R5, FGD4
328	
329	Across all focus groups, the idea of a topical treatment applied at night was embraced, citing
0_/	
330	convenience as it meant that the day's activities would be over.
330331	convenience as it meant that the day's activities would be over. <i>"A woman never has any free time during the day. So, it is good because at night, there is no</i>
330331332	convenience as it meant that the day's activities would be over. <i>"A woman never has any free time during the day. So, it is good because at night, there is no</i> <i>other activity to be done other than sleeping."</i> - R8, FGD4
 330 331 332 333 	convenience as it meant that the day's activities would be over. "A woman never has any free time during the day. So, it is good because at night, there is no other activity to be done other than sleeping." - R8, FGD4
 330 331 332 333 334 	convenience as it meant that the day's activities would be over. <i>"A woman never has any free time during the day. So, it is good because at night, there is no</i> <i>other activity to be done other than sleeping." -</i> R8, FGD4 <i>"I feel [it] is better at night because you are just resting, I don't like using it daytime because I</i>
 330 331 332 333 334 335 	 convenience as it meant that the day's activities would be over. "A woman never has any free time during the day. So, it is good because at night, there is no other activity to be done other than sleeping." - R8, FGD4 "I feel [it] is better at night because you are just resting, I don't like using it daytime because I will be walking maybe the medicine can flow [out], and that is not good." - R5, FGD2
 330 331 332 333 334 335 336 	 convenience as it meant that the day's activities would be over. <i>"A woman never has any free time during the day. So, it is good because at night, there is no other activity to be done other than sleeping." -</i> R8, FGD4 <i>"I feel [it] is better at night because you are just resting, I don't like using it daytime because I will be walking maybe the medicine can flow [out], and that is not good." -</i> R5, FGD2
 330 331 332 333 334 335 336 337 	 convenience as it meant that the day's activities would be over. "A woman never has any free time during the day. So, it is good because at night, there is no other activity to be done other than sleeping." - R8, FGD4 "I feel [it] is better at night because you are just resting, I don't like using it daytime because I will be walking maybe the medicine can flow [out], and that is not good." - R5, FGD2 "Applying it at night is very good because it is a time that I am retiring to bed. Secondly during
 330 331 332 333 334 335 336 337 338 	 convenience as it meant that the day's activities would be over. <i>"A woman never has any free time during the day. So, it is good because at night, there is no other activity to be done other than sleeping." - R8, FGD4</i> <i>"I feel [it] is better at night because you are just resting, I don't like using it daytime because I will be walking maybe the medicine can flow [out], and that is not good." - R5, FGD2</i> <i>"Applying it at night is very good because it is a time that I am retiring to bed. Secondly during the day, I will pass urine a lot but in the night once I have put it [applied the cream? Used the</i>

340	that suits meeven if I have children, they would have slept by then, even if I have a husband
341	we will be just the two of us. I am the one to choose one that suits me." – R4, FGD3
342	
343	Although most focus group discussion participants favored self-administered treatments, some
344	expressed a preference for provider-administered thermal ablation, emphasizing their comfort in
345	trusting a doctor to accurately apply the treatment to the correct area of the cervix.
346	"I feel thermos [thermal ablation] is good because when the doctor is checking he is able to
347	target the most affected area, because when we went, we were told that they look at where the
348	virus is. You see with that one [thermal ablation] they can see where the virus is and the
349	other one [self-administered cream] I am going to put but I don't know where the virus is.
350	And I feel the cream should come after you have used this other one [thermal ablation] to
351	continue with the treatment because I will not be able to see where exactly the virus is. They
352	have suspected that I have the virus, but I will not know where they are. So, I feel thermos
353	[thermal ablation] is good." - R5, FGD3
354	
355	"The reason I may only like the one I was done for [thermal ablation], than this [self-
356	administered cream], that one was done by the doctor, when she doesn't see well, she cleans
357	and confirms, if not well done she does it again until it reaches where she wants, but using
358	cream, you are in the dark, you don't know whether you have placed it well or not." – $R6$,
359	FGD2
360	
361	Similarly, participants who favored having a topical treatment applied in the clinic by a healthcare
362	professional compared to self-application expressed confidence in a doctor's ability to administer it

363	more effectively than they could themselves, particularly if they encountered side effects during the
364	application, which may cause them to hesitate with self-administration.
365	"Sometimes you can decide to try it [topical therapy] a little bit and see how it is, if you find it
366	itching you might stop using it. And you see with the doctor he will just go ahead and apply it,
367	and once he applies it is done." – R3, FGD3
368	
369	Generally, the majority of focus group participants were open to using a self-administered treatment
370	if it were accessible. Crucially, they noted that self-administered treatments at home could shield
371	them from adverse interactions with healthcare providers in clinics, such as being shouted at, which
372	some had experienced while seeking treatment for precancer.
373	"Women can be free to apply it [topical therapies], they have their own time without worry of
374	meeting a doctor, maybe one who shouted at her last timeWhat I felt when I was being
375	treated [with non-topical treatment], I was counseled first, I felt some cramps for some
376	minutes, and I even screamed a little there. The health providers touched my pelvic [area] and
377	asked me to chill."- R2, FGD3
378	
379	"I think that can be good and they can like it because most people fear the word hospital, so if
380	they can be given to go use it at home, [topical treatment] can be good." – R3, FGD2
381	Participant's Preferences Between Two Proposed Topical Therapies
382	In the FGDs, participants were introduced to two potential self-administered topical therapies for
383	cervical precancer treatment: topical 5FU cream and Artesunate suppositories. The differences
384	between the two therapies were described, including treatment length (5FU is used once every two

385 weeks for 8 applications over 16 weeks, while Artesunate is used nightly for 5 days, followed by a

386	week off, repeated for 3 cycles over six weeks), and abstinence requirements (abstinence is required
387	for 2 days after 5FU use, while abstinence is not required with Artesunate use). Participants were
388	then asked which of the two potential therapies they would prefer, if they needed to use it, based on
389	these described characteristics.
390	
391	Those who preferred the 5FU treatment did so because of the perceived ease of the application
392	regimen – once every two weeks for 16 weeks, compared to daily use for Artesunate.
393	"What makes it [5FU] better than the other one [Artesunate] for me is that maybe you have
394	traveled, so you know the one for once every two weeks, even if you apply it, even if you are on
395	a journey, it does not worry you." – R3, FGD2
396	
397	"I think 5 FU is good especially for those are not held up in their minds, there those who are
398	busy all the time and since the 5 FU is not complicated, for the AS [Artesunate], it is
399	complicated, you can forget the days, again with the menses disruption, it is not the best. I
400	think 5FU is the best option. " $- R1$, FGD4
401	
402	"The 5FU is okay because you can continue to have sex except for one day only." – R3,
403	FGD4
404	
405	"[The 5FU] will suit me because I don't have to put it all the time." - R2, FGD3
406	
407	"[I] am comfortable with it once a week, for the daily one you might have some occasions
408	like funeral and finding a place for you for application may not be easy." – R7, FGD5
409	
	19

410	Others preferred Artesunate because of its use over a significantly shorter duration – only 6 weeks
411	compared to 16 weeks for 5FU- and the possibility that condom use may not be required with its use
412	"Though the [Artesunate] is a bit tedious, you are using the medication daily, but it is a shorter
413	period of time then it doesn't have a lot of restrictions." R6, FGD1
414	
415	"The treatment that I would prefer is [Artesunate], the one where you treat for 5 days then the
416	following week you rest, then you also don't use a condom and it is a shorter period of
417	treatment than the one that goes for 16 weeks. Though the 16 weeks also have weeks when you
418	are skipping but it is a long period then it has condom use for the whole treatment period. So,
419	for me because condom will cause conflicts in my house, I would settle for [Artesunate]." – R7,
420	FGD1
421	
422	Participants noted that their treatment preferences were influenced by their perceptions of their male
423	partner's opinions of such therapies, including the requirements for condom use. Many cited that
424	abstinence for long periods of time could be a source of conflict with their male partner's
425	preferences. This was cited as a reason why therapies like Artesunate, which may not require condom
426	use or abstinence, may be preferable over 5FU which requires both for certain periods:
427	"I like where there is peacebut maybe the way the husband as we were saying, they might not
428	understand the abstinence part and even this condom use, they usually say that they cannot use
429	a condom with their partners, they feel like if you insist then there is something and this alone
430	can cause conflicts. So, I prefer [Artesunate] even if I am applying for 5 days in peace, it is
431	better because I know he is going to support me, and the medication will work well than the one
432	where you are fighting. And you know there are some that might even end up breaking the
433	rules, so peace is good." – R6, FGD1

"For me condoms can cause conflict, most men don't like using a condom and there are those

4	3	4
	~	•

- 436 who have never used a condom in their life." – R7, FGD1 437 438 Participants who did not favor Artesunate pointed out the inconvenience, especially the burden of 439 applying it every day. Furthermore, those with irregular menstrual cycles noted that 5FU was more 440 manageable due to its biweekly application schedule, which is simpler to follow than Artesunate's 441 daily regimen, which can be interrupted by irregular periods. 442 443 Considerations for Women Living with both HIV (WLWH) diagnosed with HPV 444 In the FGDs, participants who were living with HIV (WLWH) who had also tested positive for HPV 445 or cervical precancer noted feeling an increased burden. Many expressed fears about the impact of 446 the dual diagnosis on their children or other family members, as well as the challenges of managing 447 multiple medications when treating cervical precancer alongside HIV infection. 448 "It also bothered me, and it stressed me out following that I am also on HIV medication, I felt 449 very bad because I also infected my baby [with HIV]. I have been taking HIV medication 450 from 2009 up to now. So, when I imagined getting another terminal illness, I felt sad." – R6, 451 FGD3 452
 - 453 "And if I consider that I had [pre]cancer and with HIV, it was double burden. The fact that
 454 cancer can worsen and kill you I get very bad. And if I consider that I had [pre]cancer and
 455 with HIV, it was [a] double burden and so, I decided to clear with [pre]cancer which is
 456 curable." R7, FGD5
 - 457

458	One participant believed that topical treatments for cervical precancer would be insufficient due to
459	their concurrent HIV and HPV diagnoses. They harbored doubts about the effectiveness of such
460	treatments when dealing with both conditions simultaneously.
461	"According to me I feel the [topical] treatment is not 100% for those who have HIV, because
462	of our low immunity, our system is weak. So even if we are treated, we can still just get
463	[<i>cancer</i>]." – R7, FGD3
464	
465	Other participants likened the use of self-administered topical therapies among HIV-positive women
466	to the same way WLWH are prescribed antiretroviral therapies (ARVs), which they use at home to
467	treat their HIV disease. The participants drew parallels between their consistent use of ARVs at home
468	and their potential to similarly apply self-administered topical therapies in the same settings.
469	"Those who are HIV+ should go for [the topical] cream because, they go to the hospital for
470	ARVs refill, they should take cream and use it at home just the same way they take ARVs and
471	adhere to its use at home." R2, FGD4
472	
473	"ARVs is for HIV and cream is for HPV or precancer, so you just take your medication and
474	also apply your cream because they treat different things." – R7, FGD3
475	
476	Generally, participants ultimately felt that the time required to apply the topical therapies was shorter
477	in duration in the home setting versus returning to the clinic to be treated, which greatly influenced
478	their perceived acceptability and desire to use topical therapies. Regardless of HIV-seropositive
479	status, the participants noted that if they had the knowledge and the ability to apply the cream at
480	home, they would be willing to do this for the betterment of their health.

481 **Discussion**

482 In this qualitative study evaluating Kenyan women's perceptions of topical self- or provider-483 administered therapies for cervical precancer treatment, we find that participants, many of whom had 484 undergone traditional cervical precancer treatment, were highly receptive to topical therapies. We 485 found that many participants had fears following a diagnosis of HPV or cervical precancer, which 486 they had to overcome in order to undergo ablation or excisional treatment procedures. When 487 introduced to topical therapies as a potential alternative to available precancer treatments, participants 488 strongly favored topical therapies, citing reduced pain, improved accessibility, and privacy, compared 489 to the currently available provider-administered precancer treatment methods that many had 490 undergone. Most study participants expressed a strong preference for self-administration of topical 491 therapies, with many citing the lack of privacy associated with provider-administered treatments as a 492 barrier that those who had received precancer treatment had to overcome and that often discourages 493 other women from seeking treatment. Participants ' preferences varied when given an option between 494 two potential topical therapies with different characteristics and requirements for use. Some favored 495 5FU, applied every two weeks, despite its conditions for abstinence following use and consistent 496 condom use. Meanwhile, others favored Artesunate, which requires more frequent applications but 497 may have less stringent restrictions around abstinence and condom use. Despite only having had a 498 brief education session, participants showed high levels of awareness and body autonomy in the 499 discussions by displaying keen insights into potential different trade-offs associated with the two 500 topical therapies discussed, including the impact of irregular menstrual cycles on the ability to adhere 501 to a daily topical. Given the higher incidence of cervical precancer in women living with HIV, it is 502 noteworthy to highlight that HIV-positive participants in our study indicated concerns about 503 managing their HIV disease alongside a diagnosis of HPV or cervical precancer. However, most

were confident about their ability to use a self-administered topical treatment for cervical precancer, drawing on their experience with daily use of oral antiretroviral therapy to manage HIV infection.

507 To our knowledge, this is the first qualitative study to explore African women's perceptions and 508 perceived acceptability of self- or provider-administered topical therapies for cervical precancer 509 treatment. In this study of urban and peri-urban Kenyan women who had undergone cervical cancer 510 screening and a majority of whom had undergone ablation or excisional precancer treatment, many 511 expressed conflicting emotions about their treatment, explicitly highlighting the challenges they had 512 to overcome in terms of access, pain and lack of privacy often pointing to pain and privacy issues 513 when receiving provider-administered treatments. Most showed a preference for topical therapies, if 514 available, believing they would alleviate these challenges associated with conventional treatment 515 methods that often deter other women from pursuing precancer treatment. The acceptability of 516 thermal ablation, the most widely available precancer treatment method in LMICs that was approved 517 by the WHO in 2019, has been demonstrated in a few studies [28], [29]. Thermal ablation, which 518 involves the application of a heated probe to the cervix to destroy precancerous tissue, is performed 519 without local anesthesia to the cervix[6]. Studies in LMICs report that while 83.9% - 90% report no 520 or mild pain with thermal ablation, 2.5% - 16.1% report high or moderate pain with the procedure 521 [28], [29]. In our qualitative findings, some participants described thermal ablation as "too painful" 522 or "*painful just as labor pains*." Another participant noted the need to encourage women that the 523 procedure is "not very painful" and should not deter them from presenting for treatment, as the pain 524 perception is thought to keep women away from presenting for treatment. Studies on whether certain 525 women undergoing thermal ablation may require pretreatment analgesia are needed, alongside 526 considerations of the feasibility of providing of doing this. If topical therapies for cervical precancer 527 can be shown to be equally effective as ablative or excisional procedures in low- and middle-income

528 countries (LMICs), they could potentially alleviate the pain-related concerns associated with ablation529 or excision.

530

531 Our findings of participants noting challenges with treatment access and privacy concerns associated 532 with provider-administered, facility-based treatments have been demonstrated in several LMIC 533 studies. Facility-based precancer treatment access challenges in LMICs include lack of functional 534 equipment or supplies [10], [13], lack of trained providers [7], [10], [13] long distance required to 535 access treatment facilities [11], [30]. These factors significantly contribute to the existing precancer 536 treatment gaps. In a study from rural Kenya, up to 40-50% of women who screened positive and 537 were referred to a central facility did not make their follow-up appointment [11]. Similarly, in a 538 qualitative study from Malawi, women with abnormal cervical cancer screening results cited lack of 539 transportation to referral facilities and high associated costs as major reasons for not presenting for 540 treatment [30]. This is reflected in our study, where women emphasized the convenience of self-541 administered topical therapies that can be used at home, highlighted ease of access to topical self-542 administered therapies used at home, compared to facility-based treatments, which are associated 543 with high transport costs and long waiting times at the facilities as a reason they would favor topical 544 treatments. Similarly, our findings of increased privacy as a reason women prefer self-administered 545 therapies to conventional treatments have been highlighted in prior studies, which found that fear of a 546 violation of privacy associated with pelvic exams [31], [32], [33], [34], and especially when 547 performed by a male provider [33], [34], [36], are barriers to screening and precancer treatment in 548 sub-Saharan Africa. As noted by a study participant, during her ablation procedure, "two or three 549 people want to deal with your cervix, and this brings discomfort," stating that with a self-550 administered treatment, "you are alone with your husband whom you are used to, there is no fear." The use of self-administered topical therapies, which women can apply in the comfort of their own 551

homes, can be a scalable way to address both the access challenges and privacy concerns of Africanwomen.

554

555 Self-administered therapies can also promote women's autonomy and sense of agency, as highlighted 556 by our study participants, who stated that they anticipated "feel[ing]empowered" and would use it 557 correctly, as "you cannot fear your own body." The use of self-administered precancer treatment, if 558 backed by feasibility and efficacy studies in LMICs, also aligns with a recent guideline from the 559 World Health Organization that advocates for self-care interventions. As stated in the guideline, these 560 interventions have the capacity to "increase choice and autonomy," address the global shortage of 561 healthcare workers, and bring us closer to achieving universal health when made "accessible, 562 acceptable and affordable[37]." While no studies have evaluated the acceptability of self-563 administered topical cervical precancer treatment in LMICs, several studies in this setting have 564 demonstrated high acceptability of self-care interventions, including HIV self-testing [38] and the use 565 of vaginal or rectal microbicides for HIV prevention[39], [40]. Similarly, in a study on the 566 acceptability of rectal microbicide for HIV prevention among men who have sex with men in 567 Thailand, ease of use, privacy, and comfort of use at home were facilitators of uptake [41], drawing 568 similarities to our findings.

569

This study has several strengths, such as the inclusion of women who have had cervical cancer screening, as well as a deliberate oversampling of women with a history of precancer treatment. This approach ensures that the study represents the demographic that is most likely to benefit from topical therapies, hence whose perceptions are important in understanding acceptability. Similarly, the use of focus groups in the qualitative design facilitated in-depth discussion among study participants who shared similar experiences. This enabled the identification of multiple themes that impact the

acceptability of this intervention to inform feasibility studies. The study's inclusion of women living with HIV is a significant strength due to their higher risk of cervical cancer and current unmet need for accessible precancer treatment. A limitation of this study is that participants expressed theoretical acceptance of the intervention but did not actually use the topical therapies. Therefore, their views might change with actual use, an aspect future studies should explore. Another limitation was the limited time for focus groups; more time could have offered insights into household dynamics like decision-making and empowerment, potentially affecting women's perceptions of the therapies.

583 Conclusion

584 Innovative measures are urgently needed to address the gap in cervical precancer treatment in

585 LMICs, which face the highest burden of cervical cancer and limited access to existing treatments.

586 Topical therapies, self-administered by women, could be a scalable solution to meet the WHO's goal

587 of treating 90% of women with cervical precancer by 2030, aiming for cervical cancer elimination.

588 Our findings from Kenya indicate that women find these therapies acceptable and that they have the

589 potential to address significant challenges like access, privacy, and cost that hinder precancer

treatment uptake in these regions. These results support ongoing feasibility studies and call for

591 efficacy studies in this population to inform whether these treatments can be made available to

592 women.

593

594 List of Abbreviations

595 5FU: Fluorouracil

596 FGD: Focus Group Discussions

597 HIV: Human immunodeficiency virus

598 HPV: Human papillomavirus

- 599 LEEP: Loop electrosurgical excision procedure
- 600 LMIC: low-and middle-income countries
- 601 SD: standard deviation
- 602 WHO: World Health Organization
- 603 WLWH: women living with HIV
- 604
- 605 **Declarations**
- 606 Ethics approval and consent to participate
- 607 Ethical Considerations: The study was approved by the ethics review boards at Maseno University
- 608 School of Medicine in Kenya and the University of North Carolina Chapel Hill in the U.S.A. All
- 609 participants provided written informed consent prior to study participation.
- 610
- 611 **Consent for publication:** Not applicable
- 612

613 Availability of data and materials

- 614 Data are available upon reasonable request. For inquiries or to request access to the data, please
- 615 contact Chemtai Mungo at Chemtai_mungo@med.unc.edu.
- 616

617 **Competing interests**

618 The authors declare no competing financial or non-financial interests.

- 620 Funding
- 621 This research was supported by the Eunice Kennedy Shriver National Institute of Child Health &
- Human Development of the National Institutes of Health under Award Number K12HD103085 and

623	the Victoria's Secret Global Fund for Women's Cancers Career Development Award, in Partnership
624	with Pelotonia Foundation and the American Association of Cancer Research (AACR). The content
625	is solely the responsibility of the authors and does not necessarily represent the official views of the
626	National Institutes of Health. The study funders have no role in the research.
627	
628	Authors' contributions
629	CM conceptualized the study and associated clinical trials. EA and JO conducted focus group
630	discussions with study participants . GZ, SKG, RMF, and AGK worked on qualitative methodology,
631	with GZ and SKG conducting data analysis and RF leading methods section in this manuscript. AGK
632	led manuscript writing with CM and RMF. CM, AGK. EA, GZ, SKG, JO, and RMF all read and
633	approved the final version of the manuscript.
634	
635	Acknowledgments
636	The research participants and leadership of Lumumba Sub-County Hospital in Kisumu, Kenya, are
637	acknowledged.
638	
639	
640	
641	
642	
643	
644	
645	
646	

647 **References**

- H. Sung *et al.*, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
 Mortality Worldwide for 36 Cancers in 185 Countries," *CA Cancer J Clin*, vol. 71, no. 3, pp.
 209–249, May 2021, doi: 10.3322/CAAC.21660.
- A. B. M. Kharsany and Q. A. Karim, "HIV Infection and AIDS in Sub-Saharan Africa:
 Current Status, Challenges and Opportunities.," *Open AIDS J*, vol. 10, pp. 34–48, 2016, doi: 10.2174/1874613601610010034.
- E. Rohner *et al.*, "Cervical cancer risk in women living with HIV across four continents: A
 multicohort study.," *Int J Cancer*, vol. 146, no. 3, pp. 601–609, Feb. 2020, doi:
 10.1002/ijc.32260.
- 657 [4] WHO, "A Global Strategy for elimination of cervical cancer." Accessed: Mar. 26, 2020.
 658 [Online]. Available: https://www.who.int/activities/a-global-strategy-for-elimination-of659 cervical-cancer
- K. Canfell *et al.*, "Mortality impact of achieving WHO cervical cancer elimination targets: a
 comparative modelling analysis in 78 low-income and lower-middle-income countries.," *Lancet*, vol. 395, no. 10224, pp. 591–603, Feb. 2020, doi: 10.1016/S0140-6736(20)30157-4.
- 663 [6] World Health Organization (WHO), "WHO guideline for screening and treatment of cervical
 664 pre-cancer lesions for cervical cancer prevention," Geneva, 2021. [Online]. Available:
 665 https://pubmed.ncbi.nlm.nih.gov/34314129/
- C. Mungo, S. Ibrahim, E. A. Bukusi, H. H. M. Truong, C. R. Cohen, and M. Huchko, "Scaling up cervical cancer prevention in Western Kenya: Treatment access following a communitybased HPV testing approach," *International Journal of Gynecology & Obstetrics*, vol. 152, no.
 1, pp. 60–67, Jan. 2021, doi: 10.1002/IJGO.13171.
- [8] P. E. Castle, D. Murokora, C. Perez, M. Alvarez, S. C. Quek, and C. Campbell, "Treatment of cervical intraepithelial lesions," *International Journal of Gynecology & Obstetrics*, vol. 138, pp. 20–25, 2017, doi: 10.1002/ijgo.12191.
- E. Rohner *et al.*, "Mapping the cervical cancer screening cascade among women living with
 HIV in Johannesburg, South Africaa," *Int J Gynaecol Obstet*, vol. 152, no. 1, pp. 53–59, Jan.
 2021, doi: 10.1002/IJGO.13485.
- [10] H. A. Cubie and C. Campbell, "Cervical cancer screening The challenges of complete
 pathways of care in low-income countries: Focus on Malawi," *Womens Health (Lond)*, vol. 16,
 2020, doi: 10.1177/1745506520914804.
- K. Khozaim *et al.*, "Successes and challenges of establishing a cervical cancer screening and
 treatment program in western Kenya," *Int J Gynaecol Obstet*, vol. 124, no. 1, pp. 12–18, 2014,
 doi: 10.1016/J.IJGO.2013.06.035.

- [12] V. Mwenda *et al.*, "Cervical cancer programme, Kenya, 2011-2020: lessons to guide
 elimination as a public health problem," *Ecancermedicalscience*, vol. 16, 2022, doi:
 10.3332/ECANCER.2022.1442.
- K. P. Msyamboza, T. Phiri, W. Sichali, W. Kwenda, and F. Kachale, "Cervical cancer
 screening uptake and challenges in Malawi from 2011 to 2015: Retrospective cohort study," *BMC Public Health*, vol. 16, no. 1, pp. 1–6, 2016, doi: 10.1186/s12889-016-3530-y.
- K. Austad *et al.*, "Barriers to Cervical Cancer Screening and the Cervical Cancer Care
 Continuum in Rural Guatemala: A Mixed-Method Analysis," *J Glob Oncol*, vol. 4, no. 4, pp.
 1–10, Mar. 2018, doi: 10.1200/JGO.17.00228.
- [15] D. B. Vale, J. C. Teixeira, J. F. Bragança, S. Derchain, L. O. Sarian, and L. C. Zeferino,
 "Elimination of cervical cancer in low- and middle-income countries: Inequality of access and
 fragile healthcare systems," *Int J Gynaecol Obstet*, vol. 152, no. 1, pp. 7–11, Jan. 2021, doi:
 10.1002/IJGO.13458.
- M. Maiman, D. H. Watts, J. Andersen, P. Clax, M. Merino, and M. A. Kendall, "Vaginal 5fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial," *Obstetrics and Gynecology*, vol. 94, no. 6, pp. 954–961, 1999, doi: 10.1016/S0029-7844(99)00407-X.
- [17] L. Rahangdale, Q. K. Lippmann, K. Garcia, D. Budwit, J. S. Smith, and L. Van Le, "Topical
 5-flourourcil for treamtent of cervical intraepithelial Neoplasia 2□: a Randomized Controlled
 Trial," *The American Journal of Obstetrics & Gynecology*, vol. 210, no. 4, pp. 314.e1-314.e8,
 2014, doi: 10.1016/j.ajog.2013.12.042.
- [18] N. Desravines *et al.*, "Feasibility of 5-fluorouracil and imiquimod for the topical treatment of
 cervical intraepithelial neoplasias (CIN) 2/3," *Int J Gynaecol Obstet*, vol. 163, no. 3, Dec.
 2023, doi: 10.1002/IJGO.14983.
- C. L. Trimble *et al.*, "A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3).," *Gynecol Oncol*, vol. 157, no. 1, pp. 188–194, Apr. 2020, doi: 10.1016/j.ygyno.2019.12.035.
- [20] B. O. Fonseca *et al.*, "Topical Imiquimod for the Treatment of High-Grade Squamous
 Intraepithelial Lesions of the Cervix: A Randomized Controlled Trial," *Obstetrics and Gynecology*, vol. 137, no. 6, pp. 1043–1053, Jun. 2021, doi:
 10.1097/AOG.0000000004384.
- [21] C. T. Lin *et al.*, "Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia," *Taiwan J Obstet Gynecol*, vol. 51, no. 4, pp. 533–538, 2012, doi: 10.1016/j.tjog.2012.09.006.
- C. J. De Witte, A. J. M. Van De Sande, H. J. Van Beekhuizen, M. M. Koeneman, A. J. Kruse,
 and C. G. Gerestein, "Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a
 review," *Gynecol Oncol*, vol. 139, no. 2, pp. 377–384, 2015, doi:
 10.1016/J.YGYNO.2015.08.018.

- [23] C. Mungo *et al.*, "There is nothing that can prevent me from supporting her:' Men's
 perspectives on their involvement and support of women's use of topical therapy for cervical
 precancer treatment in Kenya," *medRxiv*, Dec. 2023, doi: 10.1101/2023.12.22.23300455.
- [24] C. Grimm *et al.*, "Treatment of cervical intraepithelial neoplasia with topical imiquimod: A
 randomized controlled trial," *Obstetrics and Gynecology*, vol. 120, no. 1, pp. 152–159, 2012,
 doi: 10.1097/AOG.0b013e31825bc6e8.
- [25] World Health Organization (WHO), "WHO Model List of Essential Medicines 23rd List,
 2023," Geneva, 2023. [Online]. Available: https://www.who.int/publications/i/item/WHO MHP-HPS-EML-2023.02
- 729 [26] "Female Focus Group Interview Guide: Topical precancer treatments study." Mar. 01, 2023.
- J. V. Appleton and L. King, "Journeying from the philosophical contemplation of
 constructivism to the methodological pragmatics of health services research," *J Adv Nurs*, vol.
 40, no. 6, pp. 641–648, Dec. 2002, doi: 10.1046/J.1365-2648.2002.02424.X.
- T. Metaxas *et al.*, "Acceptability and safety of thermal ablation to prevent cervical cancer in
 sub-Saharan Africa," *BMC Cancer*, vol. 22, no. 1, Dec. 2022, doi: 10.1186/S12885-02209202-2.
- C. Mungo *et al.*, "Safety and Acceptability of Thermal Ablation for Treatment of Human
 Papillomavirus Among Women Living With HIV in Western Kenya," *JCO Glob Oncol*, vol.
 6, no. 6, pp. 1024–1033, Nov. 2020, doi: 10.1200/GO.20.00035.
- J. Chapola *et al.*, "Barriers to follow-up after an abnormal cervical cancer screening result and the role of male partners: a qualitative study.," *BMJ Open*, vol. 11, no. 9, p. e049901, Sep.
 2021, doi: 10.1136/bmjopen-2021-049901.
- [31] "Knowledge and beliefs about cervical cancer screening among men in Kumasi, Ghana PubMed." Accessed: Mar. 02, 2024. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/23661828/
- A. D. Mwaka, H. R. Wabinga, and H. Mayanja-Kizza, "Mind the gaps: a qualitative study of
 perceptions of healthcare professionals on challenges and proposed remedies for cervical
 cancer help-seeking in post conflict northern Uganda," *BMC Fam Pract*, vol. 14, Dec. 2013,
 doi: 10.1186/1471-2296-14-193.
- [33] C. W. Ngugi, H. Boga, A. W. T. Muigai, P. Wanzala, and J. N. Mbithi, "Factors affecting uptake of cervical cancer early detection measures among women in Thika, Kenya," *Health Care Women Int*, vol. 33, no. 7, pp. 595–613, Jul. 2012, doi: 10.1080/07399332.2011.646367.
- [34] N. I. Ebu and J. K. Ogah, "Predictors of cervical cancer screening intention of HIV-positive
 women in the central region of Ghana," *BMC Womens Health*, vol. 18, no. 1, Feb. 2018, doi:
 10.1186/S12905-018-0534-Z.

- R. Ndejjo, T. Mukama, J. Kiguli, and D. Musoke, "Knowledge, facilitators and barriers to
 cervical cancer screening among women in Uganda: a qualitative study," *BMJ Open*, vol. 7,
 no. 6, Jun. 2017, doi: 10.1136/BMJOPEN-2017-016282.
- F. I. Modibbo *et al.*, "Qualitative study of barriers to cervical cancer screening among
 Nigerian women," *BMJ Open*, vol. 6, no. 1, 2016, doi: 10.1136/BMJOPEN-2015-008533.
- 760 [37] "WHO guideline on self-care interventions for health and well-being, 2022 revision 761 PubMed." Accessed: Mar. 04, 2024. [Online]. Available:
 762 https://pubmed.ncbi.nlm.nih.gov/35914064/
- A. R. Aluisio *et al.*, "HIV self-testing acceptability among injured persons seeking emergency
 care in Nairobi, Kenya," *Glob Health Action*, vol. 16, no. 1, 2023, doi:
 10.1080/16549716.2022.2157540.
- M. A. Abdulai *et al.*, "An assessment of the likely acceptability of vaginal microbicides for
 HIV prevention among women in rural Ghana," *BMC Womens Health*, vol. 12, Nov. 2012,
 doi: 10.1186/1472-6874-12-40.
- A. E. Tanner, "Perceptions of acceptability and utility of microbicides in Ghana, West Africa:
 A qualitative, exploratory study," *Sahara J*, vol. 5, no. 1, pp. 11–18, Apr. 2008, doi:
 10.1080/17290376.2008.9724897.
- P. A. Newman, S. Roungprakhon, and S. Tepjan, "A social ecology of rectal microbicide
 acceptability among young men who have sex with men and transgender women in Thailand," *J Int AIDS Soc*, vol. 16, no. 1, Aug. 2013, doi: 10.7448/IAS.16.1.18476.